Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139685 · ClinicalTrials.gov registry record · Phase 4
Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
NCT00139685 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 350 participants.
The verdict
NCT00139685, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
Study Summary
To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and following discontinuation of DMPA. Another group electing non-hormonal contraception or abstinence will be recruited as a reference population, across all study sites. The primary variable is BMD, measured by Dual Energy X-ray Absorptiometry (DXA). Secondary variables are: Total Body Composition\& Total Body Calcium (TBC), measured by Dual Energy X-ray Absorptiometry (DXA), and surrogate biologic BMD markers. Safety will be evaluated by adverse event reporting, laboratory evaluations, pregnancies, weight and vital signs.
Interventions
- DRUG Depo-Provera Contraceptive Injection - DP150CI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 1998-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00139685
The ClinicalTrials.gov registry entry for NCT00139685 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Depo-Provera Contraceptive Injection - DP150CI is the first listed.
NCT00139685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00139685 about?
NCT00139685 is a clinical study titled "Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception". To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and following discontinuation of DMPA. Another group electing non-hormonal contraception or abstinence will be recruited as a r...
What is the current status of trial NCT00139685?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 1998-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00139685?
The interventions under investigation include: Depo-Provera Contraceptive Injection - DP150CI (DRUG).
Who is sponsoring clinical trial NCT00139685?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.